Last edition
News about
WHO Opens Applications for 2027 Essential Medicines List Update
The World Health Organization (WHO) opens applications for the 2027 update of the Model Lists of Essential Medicines, with submissions accepted until November 6, 2026.
UK MHRA Approves Linerixibat (Lynavoy) for Biliary Disease Itch
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approves linerixibat (lynavoy) for treating itch associated with biliary tract disease, with ongoing monitoring of safety and effectiveness.
Novelty Nobility Partners with AGC Biologics to Advance Bispecific Drug Candidate
Novelty Nobility partners with AGC Biologics to advance a bispecific Antibody Drug Candidate (ADC) into GMP manufacturing, showcasing Japan’s bioprocessing expertise and AGC Biologics’ global development network.
Formosa Pharmaceuticals Partners with Singapore Eye Research Institute for Corneal Disease Therapies
Formosa Pharmaceuticals partners with Singapore Eye Research Institute to develop next-generation ophthalmic formulations using APNT nanoparticle technology and advanced clinical research expertise for corneal diseases.
Indoco Remedies Transfers Ophthalmic Division to Sunways India
Indoco Remedies transfers its ophthalmic business in India and select African markets to Sunways India under a strategic business transfer agreement to strengthen portfolio focus and growth.
Newron Pharmaceuticals Pauses US Enrollment in ENIGMA-TRS 2 Study
Newron Pharmaceuticals pauses enrolment at US sites in ENIGMA-TRS 2 study, while global ENIGMA-TRS 1 trial continues with more than 400 patients enrolled.
European Medicines Agency Launches Advisory Group to Tackle Vaccine Hesitancy
‘European Medicines’ Advisory Group aims to rebuild public trust, strengthen vaccine communication and counter misinformation across Europe.
WHO Scales Biomanufacturing Workforce Network to Advance Equitable Access
The World Health Organization (WHO) has expanded its global biomanufacturing workforce network under the 2023 training initiative, following a rigorous selection process to strengthen equitable access to medicines and global health security.
Incyte Wins US FDA Approval for Jakafi XR (Ruxolitinib)
The US Food and Drug Administration (FDA) approves Incyte Corporation’s Jakafi XR (ruxolitinib), a once-daily extended-release tablet for myelofibrosis, polycythemia vera and GVHD, offering consistent day-long exposure.
Lakewood-Amedex Biotherapeutics Reports Promising AMR Data for Nu-3 in Diabetic Foot Ulcer Treatment
Lakewood-Amedex advances Nu-3 as a potential breakthrough topical therapy to combat antibiotic-resistant infections in diabetic foot ulcers.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy